Zient

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zient

Understanding Zient

Zient is a medication used to manage high levels of cholesterol in the blood. It belongs to a class of drugs known as selective cholesterol absorption inhibitors. Unlike other cholesterol-lowering medications that work primarily in the liver, Zient acts within the small intestine to reduce the amount of cholesterol the body absorbs from the diet.

Primary Uses

Zient is typically utilized to lower total cholesterol, LDL (low-density lipoprotein) cholesterol—often referred to as "bad" cholesterol—and triglycerides. It may also be used to increase levels of HDL (high-density lipoprotein) cholesterol, commonly known as "good" cholesterol.

This medication is often prescribed for individuals with:

  • Primary Hyperlipidemia: A condition characterized by high levels of fats in the blood.
  • Homozygous Familial Hypercholesterolemia: A genetic condition that causes high cholesterol levels from birth.
  • Homozygous Sitosterolemia: A rare hereditary condition where the body accumulates plant sterols.

How It Functions

The active ingredient in Zient works by targeting a specific protein in the digestive tract that is responsible for cholesterol uptake. By inhibiting this protein, the medication prevents cholesterol from entering the bloodstream from the intestines. This includes both the cholesterol found in food and the cholesterol produced by the body that is released into the digestive system.

By reducing intestinal absorption, Zient helps lower the overall circulating cholesterol levels. It is frequently used in combination with dietary changes and, in some cases, alongside other types of cholesterol-lowering medications to achieve target lipid levels.

Regulatory References

  1. Ezetimibe: MedlinePlus Drug Information

What side effects are possible with Zient?

Possible Side Effects and Safety Information

Zient (ezetimibe) has a documented safety profile established through regulatory review, covering a range of potential adverse reactions and use restrictions. The reported side effects are categorized by frequency and the body system affected.

Adverse Reactions

Adverse reactions classified as Common (may affect up to 1 in 10 people) when Zient is used alone include abdominal pain, diarrhea, flatulence, fatigue, and joint pain (arthralgia). Infections of the upper respiratory tract and influenza-like illness have also been commonly reported.

Serious Adverse Reactions

Regulatory documentation highlights the potential for rare or very rare but serious adverse reactions, which include:

  • Hypersensitivity Reactions: Severe allergic responses such as anaphylaxis and angioedema (swelling of the face, tongue, or throat) have been reported.
  • Liver Injury: Increases in liver enzymes (transaminases) have been observed. Cases of drug-induced liver injury (DILI) have been reported in the post-marketing setting.
  • Muscle Toxicity: The risk of myopathy (muscle pain, tenderness, or weakness) and rhabdomyolysis (severe muscle breakdown) is documented. This risk is notably increased when Zient is taken concomitantly with certain other lipid-lowering drugs, such as statins or fibrates.
  • Severe Skin Reactions: Serious cutaneous adverse reactions (SCARs), including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) are reported as rare post-marketing events.

Contraindications and Restrictions

Zient is contraindicated (should not be used) in patients with a known hypersensitivity to the drug or any of its components, and in those with active liver disease or unexplained persistent elevations in liver enzymes. It is also generally not recommended for use in patients with moderate to severe hepatic impairment. Use during pregnancy and breastfeeding is contraindicated when taken in combination with a statin or fenofibrate, and caution is required when prescribing to specific patient populations, such as children (under 10 years of age is not recommended) and the elderly (over 70 years).

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation for Zient (Ezetimibe) provides specific guidance on overdose management and when urgent medical attention is required.

Documented Overdose Findings

Regulatory studies indicate that acute overexposure to Ezetimibe is generally well tolerated. High doses, significantly exceeding the typical therapeutic amount (e.g., up to 120 mg daily for 28 days), have been documented as resulting in no significant clinical or laboratory adverse events. Consequently, the official labeling does not list specific acute symptoms unique to Ezetimibe overdose.

Management Requirement Regulatory Statement
Antidote Availability No specific antidote is known for Ezetimibe overdose.
Supportive Care Treatment should consist of providing symptomatic and supportive care.

Required Emergency Actions

In the event of a suspected overdose, the primary action mandated by regulators is to contact the Poison Help line or a medical toxicologist for further guidance. Immediate emergency assistance must be sought if any life-threatening signs are present, such as if an individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Therapeutic Uses of Zient

Zient is commonly used to help manage symptoms related to systemic imbalance, specifically elevated Low-Density Lipoprotein Cholesterol (LDL-C). It plays a role in managing conditions characterized by periods of heightened symptoms such as hypercholesterolemia and mixed hyperlipidemia.

The medication is applied across domains where additional symptomatic support is needed to address persistent high cholesterol patterns. It is applied in scenarios where additional management of discomfort is required in individuals with high systemic burden, helping to maintain a sense of stability and supports general well-being. This use is relevant in clinical settings for treating primary hypercholesterolemia, mixed hyperlipidemia, Familial Hypercholesterolemia, and Homozygous Sitosterolemia.

Zient is also applicable within clinical settings that involve acute or disruptive symptom patterns, such as for adults who cannot tolerate statin therapy. It is commonly used across conditions presenting with recurrent or episodic manifestations, where it assists with maintaining functional stability by easing the overall symptom load related to specific lipid or sterol patterns.

“The medication supports long-term stability in managing symptoms related to systemic imbalance.”


Quick Fact: Support for Elevated LDL-C Patterns


Regulatory References

  1. NIH MedlinePlus overview of Ezetimibe

Eligibility and Restrictions for Use

Official Eligibility Profile

Zient (Ezetimibe) is approved for use in adults and for specific conditions in pediatric patients ge 10 years (such as Heterozygous Familial Hypercholesterolemia) and ge 9 years (for Homozygous Sitosterolemia). Use in children younger than 6 years is generally not established.


Contraindicated Populations

The medicine is strictly contraindicated in patients with a known hypersensitivity to any component. When Zient is used in combination with a statin, the combination is contraindicated in patients with active liver disease or unexplained persistent elevations in hepatic transaminase levels, and in pregnant or breastfeeding women.


Condition-Based Restrictions

Population / Condition Official Regulatory Status
Hepatic Impairment (Moderate/Severe) Not recommended (Child-Pugh B or C).
Renal Impairment No dosage adjustment required for monotherapy.
Pregnancy/Lactation (Monotherapy) Use restricted; not recommended during breastfeeding.

These official rules define the patient populations where the drug is permitted, restricted, or strictly prohibited.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Zient (Ezetimibe) around pharmacokinetic and pharmacodynamic constraints with specific substance classes.

Documented Exposure-Modifying Interactions

Interacting Substance Official Effect on Ezetimibe Exposure Regulatory Constraint
Cyclosporine Significantly increases total exposure (AUC uparrow sim 240%). Requires close monitoring.
Gemfibrozil (and certain other Fibrates) Increases total exposure (AUC uparrow sim 64%). Co-administration is generally not recommended.
Bile Acid Sequestrants (e.g., Cholestyramine) Decreases total exposure (AUC downarrow sim 55%). Requires mandatory timing separation.

Pharmacodynamic Interaction Risks

Co-administration with Statins (HMG-CoA reductase inhibitors) is associated with an increased risk of skeletal muscle effects (myopathy/rhabdomyolysis) compared to taking Ezetimibe alone. Combining Ezetimibe with Fibrates is documented to increase the risk of cholelithiasis (gallstone formation) and gallbladder disease.

Administration and Clearance Constraints

The regulatory label mandates that Zient must be administered at least 2 hours before or 4 hours after a bile acid sequestrant to counter reduced absorption. While Zient is cleared primarily by glucuronidation, it is officially documented as neither an inhibitor nor an inducer of major CYP450 enzymes (1A2, 2D6, 2C8/9, 3A4), suggesting a low potential for metabolic drug-drug interactions via those pathways. Increased total Ezetimibe exposure is noted in patients with severe renal impairment, and the medication is not recommended in cases of moderate to severe hepatic impairment.

Mechanism of Action

Zient, whose active compound is ezetimibe, acts as a selective inhibitor of intestinal and biliary cholesterol absorption. Its biological target is the Niemann-Pick C1-Like 1 (NPC1L1) protein, a critical sterol transporter situated on the brush border of enterocytes in the small intestine, and on hepatocytes. The drug localizes at this intestinal site and non-competitively blocks the function of NPC1L1. This molecular interaction prevents the facilitated uptake of free cholesterol and phytosterols from the intestinal lumen into the enterocyte. The intracellular consequence is a reduction in the overall mass of cholesterol delivered from the intestine to the liver via the portal circulation. In response to the decreased hepatic cholesterol pool, there is a system-level physiological up-regulation of cholesterol clearance from the bloodstream, primarily mediated by increased expression and activity of the Low-Density Lipoprotein (LDL) receptors on the hepatocyte surface. This cascade promotes the removal of circulating apolipoprotein B-containing lipoproteins.

Dosage and Administration Information

How Zient is Used: Administration Guidelines

Zient is prescribed as a selective cholesterol absorption inhibitor and is intended for long-term, continuous administration as part of a lipid management plan. All instructions regarding use, dosing, and timing are defined within established therapeutic guidelines.

The medication is available as a single, fixed-strength 10 mg tablet and is administered via the oral route.

Feature Instruction Summary
Standard Adult Dose 10 mg once daily. This is also the maximum recommended daily dose.
Frequency & Timing Taken once daily, and administration is flexible; it may be consumed with or without food and at any time of the day.
Pediatric Use Approved for the standard 10 mg dose for patients 10 years of age and older.
Missed Dose Rule If a dose is missed, it should be taken as soon as possible, but users must not take more than 10 mg in a single day.

Special Procedural Constraints

Administration of Zient requires attention to specific drug combinations. If the medication is used alongside a bile acid sequestrant (such as cholestyramine), a key procedural rule must be followed: Zient must be taken at least 2 hours before or 4 hours after the sequestrant to ensure proper absorption and effectiveness.

Dosing in Specific Populations

Dosing remains consistent for most adult populations. No dose adjustment is required for older adults or for patients with renal impairment. However, guidance advises against the use of the medicine in patients with moderate or severe hepatic (liver) impairment. This fixed-dose approach simplifies the routine for continuous, chronic therapy.

Recent Clinical Evidence

Research Evidence Supporting Lipid Modification (LDL-C)

Research examining Zient (Ezetimibe) for high blood cholesterol, known as primary hypercholesterolemia or mixed dyslipidemia, includes Randomized Controlled Trials (RCTs) and supporting systematic reviews. These short-term studies, often lasting 6 to 12 weeks, were conducted on adults to measure changes in certain fatty substances in the blood. Researchers monitored key biomarkers, primarily Low-Density Lipoprotein Cholesterol (LDL-C), as well as total cholesterol and triglycerides. These studies were designed to track how these measurements evolved when the medicine was used alone or when it was added to existing statin therapy.

Studies monitored these lipid measurements and reported patterns observed during the study period. Initial findings helped contextualize how the medicine was observed to affect these blood-level measurements. The evidence contributes to understanding the patterns measured during the study period. However, a key limitation in the initial body of evidence is that the primary focus was on indirect measurements (such as blood biomarker changes). The use of indirect measurements generally means the studies were designed for biomarker changes, not the long-term tracking of major clinical events.


Evidence from Long-Term Cardiovascular Outcome Trials

Later research explored outcomes related to patient health over extended periods, examining the medicine's role in this context. This involved large-scale, long-duration Randomized Trials that followed patients for many years (median follow-up often spanning 6 to 7 years). The studies were specifically designed to track the occurrence of major atherosclerotic events over time.

Studies primarily included high-risk adults who had recently been stabilized after an Acute Coronary Syndrome (ACS). These trials tracked a composite outcome of major cardiovascular (CV) events, including non-fatal stroke and non-fatal heart attack. The findings concerning these major CV events were reported within the context of combination therapy—the medicine was used in addition to a statin. Evidence exploring long-term CV outcomes when Zient is used as a monotherapy in this specific high-risk population is less defined.


Key Limitations and Areas for Further Research

The scientific literature and regulatory reviews point to several areas where the evidence remains limited or warrants further investigation. A persistent limitation is the reliance on indirect measurements (LDL-C levels) in some foundational studies. Furthermore, data for certain specialized groups, such as those with severe genetic dyslipidemias, are derived from studies with modest sample sizes due to the rarity of the condition. While the research describes the patterns observed so far, there are no dedicated long-term trials examining the medicine as a stand-alone therapy for major cardiovascular event prevention. Research is ongoing.

Frequently Asked Questions (FAQ)

Common questions about Zient (FAQ)


Q: What is the difference between Zient and the generic version?

The generic version, which contains the active ingredient Ezetimibe, is approved by regulatory bodies as being bioequivalent to the brand name Zient. This means the generic version is required to meet the same quality, strength, and route of administration, and is considered bioequivalent to the brand-name product.


Q: Is Zient the same type of medicine as [similar drug name]?

Zient is officially classified as a selective cholesterol absorption inhibitor. This identity means it works by blocking cholesterol uptake in the small intestine, which is a mechanism different from drug classes like statins or fibrates. This distinct approach allows it to be used alone or combined with other lipid-lowering therapies.


Q: Why is Zient used for [secondary approved condition] as well?

In addition to its primary use for high blood cholesterol, the drug is also approved for use in certain rare genetic conditions. These secondary uses include treating Homozygous Familial Hypercholesterolemia and Homozygous Sitosterolemia.


Q: How quickly can I expect Zient to start working, and when is the full benefit assessed?

Studies indicate that measurable changes in blood lipid levels can be seen early in treatment. The clinical effectiveness of Zient is typically assessed by a healthcare provider as early as 4 weeks after the start of therapy.


Q: Can I take Zient with my morning coffee?

Official product information notes that the medicine can be taken with or without food and at any time of the day. This indicates flexibility regarding administration with non-alcoholic beverages like coffee.


Q: Are there any specific foods or drinks I should avoid while using Zient?

Official product information states that Zient may be taken with or without food. No specific restrictions on consuming particular foods or beverages are noted in the primary regulatory labeling.


Q: What common supplements or herbal products interact with Zient?

The official product monograph suggests that patients inform their healthcare provider about all medicines they are taking, including herbal remedies, vitamins, or other supplements. Specific interactions with general herbal products are not commonly noted unless a significant risk is established.


Q: Can Zient be taken with multivitamins?

Clinical studies found that Zient did not significantly affect the plasma levels of fat-soluble vitamins (A, D, and E). While this supports concurrent use, official guidance suggests informing a healthcare provider of all supplements, including multivitamins.


Q: What is the risk of having a serious interaction with Zient?

The official label notes specific interactions that require attention. Co-administration with the fibrate gemfibrozil is generally not recommended, and close monitoring is required if Zient is taken alongside cyclosporine. The label also notes a required timing separation if Zient is taken alongside a bile acid sequestrant.


Q: Does Zient interact with over-the-counter pain relievers or common allergy medications?

The official label does not specifically list interactions with common over-the-counter (OTC) pain or allergy relievers. However, official guidance suggests that patients inform their healthcare provider of all non-prescription products they take to check for potential drug interactions.


Q: Why do official documents mention [specific caution] regarding Zient?

Cautions are mentioned in official documents to ensure patient safety based on documented evidence. For instance, the label notes the potential for skeletal muscle effects (myopathy) which were observed in clinical trials, particularly when the drug is used in combination with statins or fibrates.


Q: Can Zient be taken by people who have [common chronic condition]?

Regulatory documents define specific patient populations for whom Zient is restricted, such as those with active liver disease or moderate to severe hepatic impairment. Any questions regarding chronic conditions should be discussed with a healthcare provider.


Q: Do I need any special monitoring or blood tests while on Zient?

Official documents recommend considering a liver function test at the start of treatment with Zient. Further blood tests and monitoring may be performed based on the clinical judgment of a healthcare provider.


Q: Is the long-term safety profile of Zient well-established and is it safe to use for a long time?

Official information indicates that Zient is intended for long-term, continuous administration as part of a patient's lipid management plan. The safety profile has been established over time through long-duration clinical trials and extensive post-marketing surveillance.


Q: What is the purpose of the black box warning on Zient's official label?

The FDA Prescribing Information for Zient explicitly states that the drug does not have a Boxed Warning. This type of warning, sometimes called a Black Box Warning, is reserved for drugs with certain severe safety concerns.


Q: Is Zient an opioid or a controlled substance?

According to regulatory authorities, Zient is classified as a prescription-only medicine but is not considered a controlled substance or an opioid. Its active ingredient, ezetimibe, is not a scheduled drug under US law.


Q: Is there a link between Zient and mood changes?

The official Postmarketing Experience section lists depression among the adverse reactions reported by patients taking the medication. This type of information is collected through ongoing safety surveillance after the drug is approved.


Q: Are there any limitations on activity while using Zient?

The known adverse reactions list includes effects like dizziness and fatigue. Patients who experience these side effects are advised to exercise caution when engaging in activities that require concentration, such as driving or operating heavy machinery.


Q: Can Zient be split in half if the tablet has a score line?

The official product information describes the 10 mg tablet as a capsule-shaped tablet with no score line. The official product information does not contain instructions for altering the tablet, such as splitting, cutting, or crushing.


Q: How long does Zient stay in your system after you stop taking it?

The active compound, ezetimibe, and its primary active metabolite have an elimination half-life of approximately 22 hours. This means that this is the approximate time required for half of the drug to be eliminated from the body.


Q: What are the ingredients in Zient besides the active compound?

The Zient tablet is composed of the active compound Ezetimibe, along with several inactive ingredients, or excipients. These include lactose monohydrate, microcrystalline cellulose, corn starch, crospovidone, povidone, magnesium stearate, sodium lauryl sulfate, and sodium stearyl fumarate.

How should Zient be stored and disposed of?

Official Storage and Disposal Requirements

Zient (ezetimibe) tablets must be handled and stored in strict accordance with government-approved labeling to maintain product stability and safety.

Storage Component Official Requirement
Temperature Store at room temperature; do not store above 30 C (86 F).
Protection Keep the tablets protected from moisture and stored in the original container (blister pack).
Child Safety Keep out of the sight and reach of children at all times.

Disposal Instructions

Disposal of unused or expired Zient must follow national and local pharmaceutical waste handling requirements. Regulatory mandates state that the medicine must not be disposed of via general household waste or flushed into wastewater, to prevent environmental contamination. Unused product should be returned to a pharmacy or a designated collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zient found in:

A-Z Index: